Pharsight

1. Ingrezza patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8039627	NEUROCRINE	Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto	Apr, 2031 (7 years from now)
US10065952	NEUROCRINE	Valbenazine salts and polymorphs thereof	Oct, 2036 (13 years from now)
US10844058	NEUROCRINE	Valbenazine salts and polymorphs thereof	Oct, 2036 (13 years from now)
US10851103	NEUROCRINE	Valbenazine salts and polymorphs thereof	Oct, 2036 (13 years from now)
US10851104	NEUROCRINE	Valbenazine salts and polymorphs thereof	Oct, 2036 (13 years from now)
US10919892	NEUROCRINE	Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)	Dec, 2036 (13 years from now)
US10906902	NEUROCRINE	Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)	Dec, 2036 (13 years from now)
US10906903	NEUROCRINE	Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)	Dec, 2036 (13 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8357697	NEUROCRINE	Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto	Nov, 2027 (4 years from now)
US10874648	NEUROCRINE	Methods for the administration of certain VMAT2 inhibitors	Oct, 2037 (14 years from now)
US11040029	NEUROCRINE	Methods for the administration of certain VMAT2 inhibitors	Oct, 2037 (14 years from now)
US10912771	NEUROCRINE	Methods for the administration of certain VMAT2 inhibitors	Oct, 2037 (14 years from now)
US10952997	NEUROCRINE	Methods for the administration of certain VMAT2 inhibitors	Oct, 2037 (14 years from now)
US10857148	NEUROCRINE	Methods for the administration of certain VMAT2 inhibitors	Oct, 2037 (14 years from now)
US10857137	NEUROCRINE	Methods for the administration of certain VMAT2 inhibitors	Oct, 2037 (14 years from now)
US10993941	NEUROCRINE	Methods for the administration of certain VMAT2 inhibitors	Oct, 2037 (14 years from now)
US11026939	NEUROCRINE	High dosage valbenazine formulation and compositions, methods, and kits related thereto	Sep, 2038 (14 years from now)
US11311532	NEUROCRINE	High dosage valbenazine formulation and compositions, methods, and kits related thereto	Sep, 2038 (14 years from now)
US11026931	NEUROCRINE	Methods for the administration of certain VMAT2 inhibitors	Aug, 2039 (15 years from now)
US10940141	NEUROCRINE	Methods for the administration of certain VMAT2 inhibitors	Aug, 2040 (16 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Apr 11, 2022

Drugs and Companies using VALBENAZINE TOSYLATE ingredient

NCE-1 date: 2021-04-11

Market Authorisation Date: 11 April, 2017

Treatment: Treatment of tardive dyskinesia; Method of administering valbenazine while avoiding concomitant use of a strong cyp3a4 inducer; Method of treating tardive dyskinesia while avoiding concomitant use of ...

Dosage: CAPSULE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
40 mg and 80 mg	12 Apr, 2021	4		10 Aug, 2040
60 mg	14 Feb, 2022	1		10 Aug, 2040

Strength	Dosage	Availability
EQ 40MG BASE	CAPSULE;ORAL	Prescription
EQ 60MG BASE	CAPSULE;ORAL	Prescription
EQ 80MG BASE	CAPSULE;ORAL	Prescription

INGREZZA family patents

2. Ongentys patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8907099	NEUROCRINE	Nitrocatechol derivatives as COMT inhibitors	May, 2027 (3 years from now)
US8168793	NEUROCRINE	Nitrocatechol derivatives as COMT inhibitors	Apr, 2029 (5 years from now)
US9630955	NEUROCRINE	Chemical compound useful as intermediate for preparing a catechol-O-methyltransferase inhibitor	Dec, 2032 (9 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9550759	NEUROCRINE	Nitrocatechol derivatives as COMT inhibitors	Jul, 2026 (2 years from now)
US9745290	NEUROCRINE	Dosage regimen for COMT inhibitors	Oct, 2027 (4 years from now)
US8524746	NEUROCRINE	Dosage regimen for COMT inhibitors	Jul, 2029 (5 years from now)
US10071085	NEUROCRINE	Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof	Mar, 2030 (6 years from now)
US10583130	NEUROCRINE	Pharmaceutical formulations compromising nitrocatechol derivatives and methods of making thereof	Mar, 2030 (6 years from now)
US10357468	NEUROCRINE	Medicaments for slowing Parkinson's disease	May, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Apr 24, 2025

Drugs and Companies using OPICAPONE ingredient

NCE-1 date: 2024-04-24

Market Authorisation Date: 24 April, 2020

Treatment: Method of inhibiting comt in the periphery; Method of treating parkinson's disease; Method of reducing o-methylation of l-dopa; Adjunctive treatment to levodopa/carbidopa in patients with parkinson's ...

Dosage: CAPSULE;ORAL